These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31766831)

  • 1. Designer drugs – still a threat?
    Rozenek EB; Wilczyńska K; Górska M; Waszkiewicz N
    Przegl Epidemiol; 2019; 73(3):337-347. PubMed ID: 31766831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cannabinoid and cathinone designer drugs - the workings and selected methods of analysis].
    Nędza J; Polaniak R; Bułdak RJ; Majchrzak M; Margasiń-Ska J; Rojkiewicz M; Celiński R; Grochowska-Niedworok E
    Pol Merkur Lekarski; 2016 Jul; 41(241):56-59. PubMed ID: 27734824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
    Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
    Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Synthetic cannabinoids--the new "legal high" drugs].
    Berkovitz R; Arieli M; Marom E
    Harefuah; 2011 Dec; 150(12):884-7, 937. PubMed ID: 22352277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An expanding world of new psychoactive substances-designer benzodiazepines.
    Zawilska JB; Wojcieszak J
    Neurotoxicology; 2019 Jul; 73():8-16. PubMed ID: 30802466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of the use of designer drugs in Poland--review of the published evidence.
    Kryska S
    Przegl Epidemiol; 2016; 70(1):35-9, 121-3. PubMed ID: 27344472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Agents of Substance Use/Misuse.
    Michienzi AE; Borek HA
    Emerg Med Clin North Am; 2022 May; 40(2):265-281. PubMed ID: 35461623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
    Orsolini L; Corkery JM; Chiappini S; Guirguis A; Vento A; De Berardis D; Papanti D; Schifano F
    Curr Neuropharmacol; 2020; 18(9):809-837. PubMed ID: 31933443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psychoactive plant species--actual list of plants prohibited in Poland].
    Simonienko K; Waszkiewicz N; Szulc A
    Psychiatr Pol; 2013; 47(3):499-510. PubMed ID: 23885543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
    Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
    J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designer drugs: a medicinal chemistry perspective.
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Landscape of Designer Drugs.
    Kacinko SL; Papsun DM
    Methods Mol Biol; 2019; 1872():129-135. PubMed ID: 30350286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Not for human consumption": a review of emerging designer drugs.
    Musselman ME; Hampton JP
    Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Designer drugs in Finland].
    Tacke U; den Hollander B; Simojoki K; Korpi ER; Pihlainen K; Alho H
    Duodecim; 2011; 127(19):2027-36. PubMed ID: 22073534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New psychoactive substances and their prevalence in the Czech Republic].
    Mravčík V; Běláčková V; Grohmannová K; Zábranský T
    Cas Lek Cesk; 2015; 154(5):216-21. PubMed ID: 26612328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral fluid drug analysis in the age of new psychoactive substances.
    Øiestad EL; Øiestad ÅM; Gjelstad A; Karinen R
    Bioanalysis; 2016 Apr; 8(7):691-710. PubMed ID: 26964619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designer drugs: mechanism of action and adverse effects.
    Luethi D; Liechti ME
    Arch Toxicol; 2020 Apr; 94(4):1085-1133. PubMed ID: 32249347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of current trends in the abuse of psychotropic substances and plants in Japan.
    Kikura-Hanajiri R; Uchiyama N; Goda Y
    Leg Med (Tokyo); 2011 May; 13(3):109-15. PubMed ID: 21377397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of new psychoactive substances to mimic prescription drugs: The trend in France.
    Batisse A; Eiden C; Peyriere H; Djezzar S;
    Neurotoxicology; 2020 Jul; 79():20-24. PubMed ID: 32240674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of new designer drugs and their legal status in Japan].
    Kikura-Hanajiri R; Uchiyama N; Kawamura M; Ogata J; Goda Y
    Yakugaku Zasshi; 2013; 133(1):31-40. PubMed ID: 23292017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.